Literature DB >> 12784998

Roles of hepatocyte growth factor (HGF) activator and HGF activator inhibitor in the pericellular activation of HGF/scatter factor.

Hiroaki Kataoka1, Shiro Miyata, Shunro Uchinokura, Hiroshi Itoh.   

Abstract

The activation of hepatocyte growth factor (HGF)/scatter factor (SF) in an extracellular milieu is a critical limiting step in HGF/SF-induced signaling that is believed to have important roles in invasive growth of tumor cells and regeneration of injured tissue. This activation is caused by a proteolytic cleavage at the bond between Arg494-Val495 in the single-chain HGF/SF precursor, generating an active two-chain heterodimeric form. The HGF activator (HGFA) is a coagulation factor XII-like serine proteinase critically involved in this process in injured tissues including tumor tissues. In the past several years, the identification of endogenous HGFA inhibitors (HAIs) has provided detailed knowledge of the regulation of HGFA activity. Currently, two types of HAIs, namely HAI-1 and HAI-2, have been reported. Both are Kunitz-type serine proteinase inhibitors and inhibit not only HGFA but also other serine proteinases, such as membrane-type serine protease 1 (matriptase), plasmin, trypsin and kallikreins. HAIs are of particular interest because they are synthesized as type-I transmembrane proteins. Therefore, HAIs must have important regulatory roles in a cell surface proteolytic reaction, which has emerged as an important mechanism for the generation of biologically active proteins mediating a diverse range of cellular functions. This review is a summary and interpretation of recent data regarding the regulation of pericellular HGF/SF activation mediated by HGFA and HAIs and includes a discussion of the possible role of the type I transmembrane Kunitz-type inhibitor in pericellular proteolysis.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12784998     DOI: 10.1023/a:1023051500010

Source DB:  PubMed          Journal:  Cancer Metastasis Rev        ISSN: 0167-7659            Impact factor:   9.264


  43 in total

1.  Hepatocyte growth factor activator inhibitor type 1 (HAI-1) is required for branching morphogenesis in the chorioallantoic placenta.

Authors:  Hiroyuki Tanaka; Koki Nagaike; Naoki Takeda; Hiroshi Itoh; Kazuyo Kohama; Tsuyoshi Fukushima; Shiro Miyata; Shuichiro Uchiyama; Shunro Uchinokura; Takeshi Shimomura; Keiji Miyazawa; Naomi Kitamura; Gen Yamada; Hiroaki Kataoka
Journal:  Mol Cell Biol       Date:  2005-07       Impact factor: 4.272

2.  Expression of hepatocyte growth factor activator inhibitor type 1 in endothelial cells.

Authors:  Yutaka Akiyama; Miyuki Nagai; Wataru Komaki; Kousuke Marutsuka; Yujiro Asada; Hiroaki Kataoka
Journal:  Hum Cell       Date:  2006-08       Impact factor: 4.174

3.  Secretory expression and characterization of a recombinant-deleted variant of human hepatocyte growth factor in Pichia pastoris.

Authors:  Zhi-Min Liu; Hong-Liang Zhao; Chong Xue; Bing-Bing Deng; Wei Zhang; Xiang-Hua Xiong; Bing-Fen Yang; Xue-Qin Yao
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

4.  Hepatocyte growth factor activator inhibitor type 1 maintains the assembly of keratin into desmosomes in keratinocytes by regulating protease-activated receptor 2-dependent p38 signaling.

Authors:  Makiko Kawaguchi; Ai Kanemaru; Akira Sawaguchi; Koji Yamamoto; Takashi Baba; Chen-Yong Lin; Michael D Johnson; Tsuyoshi Fukushima; Hiroaki Kataoka
Journal:  Am J Pathol       Date:  2015-04-01       Impact factor: 4.307

5.  Trans-ethnic meta-analysis identifies common and rare variants associated with hepatocyte growth factor levels in the Multi-Ethnic Study of Atherosclerosis (MESA).

Authors:  Nicholas B Larson; Cecilia Berardi; Paul A Decker; Christina L Wassel; Phillip S Kirsch; James S Pankow; Michele M Sale; Mariza de Andrade; Hugues Sicotte; Weihong Tang; Naomi Q Hanson; Michael Y Tsai; Kent D Taylor; Suzette J Bielinski
Journal:  Ann Hum Genet       Date:  2015-05-22       Impact factor: 1.670

6.  Enhanced expression of hepatocyte growth factor activator inhibitor type 2-related small peptide at the invasive front of colon cancers.

Authors:  S Uchiyama; H Itoh; S Naganuma; K Nagaike; T Fukushima; H Tanaka; R Hamasuna; K Chijiiwa; H Kataoka
Journal:  Gut       Date:  2006-06-29       Impact factor: 23.059

7.  Inhibitors of HGFA, Matriptase, and Hepsin Serine Proteases: A Nonkinase Strategy to Block Cell Signaling in Cancer.

Authors:  Zhenfu Han; Peter K W Harris; Darin E Jones; Ryan Chugani; Tommy Kim; Manjula Agarwal; Wei Shen; Scott A Wildman; James W Janetka
Journal:  ACS Med Chem Lett       Date:  2014-10-09       Impact factor: 4.345

8.  Loss of HGF activator inhibits foveolar hyperplasia induced by oxyntic atrophy without altering gastrin levels.

Authors:  Yukinori Yamagata; Susumu Aikou; Tsuyoshi Fukushima; Hiroaki Kataoka; Yasuyuki Seto; Hiroyasu Esumi; Michio Kaminishi; James R Goldenring; Sachiyo Nomura
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2012-10-11       Impact factor: 4.052

9.  Plasma macrophage-stimulating protein and hepatocyte growth factor levels are associated with prostate cancer progression.

Authors:  Satoru Sugie; Shoichiro Mukai; Koji Yamasaki; Toyoharu Kamibeppu; Hiromasa Tsukino; Toshiyuki Kamoto
Journal:  Hum Cell       Date:  2015-08-07       Impact factor: 4.174

10.  Expression of hepatocyte growth factor activator inhibitor type 1 on the epithelial cell surface is regulated by hypoxic and oxidative stresses.

Authors:  Wataru Komaki; Tsuyoshi Fukushima; Hiroyuki Tanaka; Hiroshi Itoh; Etsuo Chosa; Hiroaki Kataoka
Journal:  Virchows Arch       Date:  2008-09-04       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.